Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.

BACKGROUND: A significant percentage of patients treated with ustekinumab may lose response. Our aim was to evaluate the short-term efficacy and safety of intravenous re-induction with ustekinumab in patients with Crohn's disease who have lost the response to the treatment. METHODS: This is a r...

Full description

Bibliographic Details
Authors: Bermejo F, Jiménez L, Algaba A, Vela M, Bastida G, Merino O, López-García A, Melcarne L, Rodríguez-Lago I, de la Maza S, Bouhmidi A, Barreiro-de Acosta M, López-Serrano P, Carrillo-Palau M, Mesonero F, Orts B, Bonillo D, Granja A, Guerra I
Format: article
Status:Published version
Publication Date:2022
Country:España
Institution:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repository:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p8221
Online Access:https://isabial.portalinvestigacion.com/publicaciones8221
Access Level:Open access
Keyword:Crohn’s disease
loss of response
re-induction
ustekinumab
id ES_628b0e8e9bfbeda4d980f7f92aec7b7b
oai_identifier_str oai:isabial.fundanetsuite.com:p8221
network_acronym_str ES
network_name_str España
repository_id_str
spelling Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.Bermejo FJiménez LAlgaba AVela MBastida GMerino OLópez-García AMelcarne LRodríguez-Lago Ide la Maza SBouhmidi ABarreiro-de Acosta MLópez-Serrano PCarrillo-Palau MMesonero FOrts BBonillo DGranja AGuerra ICrohn’s diseaseloss of responsere-inductionustekinumabBACKGROUND: A significant percentage of patients treated with ustekinumab may lose response. Our aim was to evaluate the short-term efficacy and safety of intravenous re-induction with ustekinumab in patients with Crohn's disease who have lost the response to the treatment. METHODS: This is a retrospective, observational, multicenter study. Treatment efficacy was measured at week 8 and 16; clinical remission was defined when the Harvey-Bradshaw Index was =4 points, and clinical response was defined as a decrease of =3 points in the index compared with the baseline. Adverse events and treatment decisions after re-induction were also collected. RESULTS: Fifty-three patients from 13 centers were included. Forty-nine percent had previously failed to respond to 2 biological treatments, and 24.5% had failed to respond to 3. The average exposure time to ustekinumab before re-induction was 17.7 ± 12.8 months. In 56.6% of patients, the administration interval had been shortened to every 4 to 6 weeks before re-induction. At week 8 and 16 after re-induction, 49.0% (n = 26) and 43.3% (n = 23), respectively, were in remission, whereas 64.1% (n = 34) and 52.8% (n = 28) had a clinical response. Patients who achieved remission at week 16 had lower C-reactive protein levels than those who did not respond (2.8 ± 1.6 vs 12.5 ± 9.5 mg/dL; P = 0.001). No serious adverse events related to re-induction were observed. CONCLUSION: Intravenous re-induction with ustekinumab is an effective and safe strategy that recovers the response in approximately half of the patients with refractory Crohn's disease who experience a loss of response. Re-induction can be attempted before switching out of the therapy class.OXFORD UNIV PRESS INC2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones8221INFLAMMATORY BOWEL DISEASESISSN: 10780998ISSNe: 15364844reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p82212026-06-12T10:20:37Z
dc.title.none.fl_str_mv Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
title Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
spellingShingle Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F
Crohn’s disease
loss of response
re-induction
ustekinumab
title_short Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
title_full Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
title_fullStr Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
title_full_unstemmed Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
title_sort Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
dc.creator.none.fl_str_mv Bermejo F
Jiménez L
Algaba A
Vela M
Bastida G
Merino O
López-García A
Melcarne L
Rodríguez-Lago I
de la Maza S
Bouhmidi A
Barreiro-de Acosta M
López-Serrano P
Carrillo-Palau M
Mesonero F
Orts B
Bonillo D
Granja A
Guerra I
author Bermejo F
author_facet Bermejo F
Jiménez L
Algaba A
Vela M
Bastida G
Merino O
López-García A
Melcarne L
Rodríguez-Lago I
de la Maza S
Bouhmidi A
Barreiro-de Acosta M
López-Serrano P
Carrillo-Palau M
Mesonero F
Orts B
Bonillo D
Granja A
Guerra I
author_role author
author2 Jiménez L
Algaba A
Vela M
Bastida G
Merino O
López-García A
Melcarne L
Rodríguez-Lago I
de la Maza S
Bouhmidi A
Barreiro-de Acosta M
López-Serrano P
Carrillo-Palau M
Mesonero F
Orts B
Bonillo D
Granja A
Guerra I
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Crohn’s disease
loss of response
re-induction
ustekinumab
topic Crohn’s disease
loss of response
re-induction
ustekinumab
description BACKGROUND: A significant percentage of patients treated with ustekinumab may lose response. Our aim was to evaluate the short-term efficacy and safety of intravenous re-induction with ustekinumab in patients with Crohn's disease who have lost the response to the treatment. METHODS: This is a retrospective, observational, multicenter study. Treatment efficacy was measured at week 8 and 16; clinical remission was defined when the Harvey-Bradshaw Index was =4 points, and clinical response was defined as a decrease of =3 points in the index compared with the baseline. Adverse events and treatment decisions after re-induction were also collected. RESULTS: Fifty-three patients from 13 centers were included. Forty-nine percent had previously failed to respond to 2 biological treatments, and 24.5% had failed to respond to 3. The average exposure time to ustekinumab before re-induction was 17.7 ± 12.8 months. In 56.6% of patients, the administration interval had been shortened to every 4 to 6 weeks before re-induction. At week 8 and 16 after re-induction, 49.0% (n = 26) and 43.3% (n = 23), respectively, were in remission, whereas 64.1% (n = 34) and 52.8% (n = 28) had a clinical response. Patients who achieved remission at week 16 had lower C-reactive protein levels than those who did not respond (2.8 ± 1.6 vs 12.5 ± 9.5 mg/dL; P = 0.001). No serious adverse events related to re-induction were observed. CONCLUSION: Intravenous re-induction with ustekinumab is an effective and safe strategy that recovers the response in approximately half of the patients with refractory Crohn's disease who experience a loss of response. Re-induction can be attempted before switching out of the therapy class.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones8221
url https://isabial.portalinvestigacion.com/publicaciones8221
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv OXFORD UNIV PRESS INC
publisher.none.fl_str_mv OXFORD UNIV PRESS INC
dc.source.none.fl_str_mv INFLAMMATORY BOWEL DISEASES
ISSN: 10780998
ISSNe: 15364844
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409504968310784
score 15,811543

Similar Items